1. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer
- Author
-
D Pilz, G. Schwab, Hannes Wandt, H Egger, K. Schäfer, Th Denzel, W. M. Gallmeier, A Both, and J. Birkmann
- Subjects
Melphalan ,Adult ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Urology ,Filgrastim ,Transplantation, Autologous ,Carboplatin ,chemistry.chemical_compound ,Ototoxicity ,Hearing ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,Medicine ,Humans ,Etoposide ,Ovarian Neoplasms ,Transplantation ,Chemotherapy ,Leukopenia ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Hematopoietic Stem Cell Mobilization ,Surgery ,chemistry ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
To assess high-dose carboplatin chemotherapy with or without paclitaxel with filgrastim mobilized peripheral blood progenitor cell (PBPC) support in a phase I/II study, a total of 21 patients with mostly chemonaive disease received four cycles of high-dose chemotherapy. Cycle 1 (cyclophosphamide, 6 g/m2) was followed by two cycles of carboplatin (1600 mg/m2 or 1800 mg/m2). Cycle 4 consisted of carboplatin (1600 mg/m2), etoposide (1600 mg/m2), and melphalan (140 mg/m2). Further chemotherapy intensification was achieved by adding paclitaxel (175 mg/m2) to all cycles with a fixed carboplatin dose (1600 mg/m2). Ototoxicity was dose-limiting for escalation of sequential cycles of carboplatin. Grade 2 and grade 3 ototoxicity, hearing loss not requiring a hearing aid, or hearing loss correctable with a hearing aid, was observed with carboplatin at 1800 mg/m2. The maximum tolerated dose (MTD) of sequential carboplatin, therefore, was identified in this study as 1600 mg/m2. After cycles 1, 2, 3 and 4 the median duration of leukopenia (
- Published
- 1999